"An advanced Cancer Center where over 1,200 highly sub-specialized professionals work together in a multidisciplinary approach to bring customized solutions in a friendly and engaging environment to every patient."

During the past decade, John Theurer Cancer Center at Hackensack University Medical Center conducted 117 clinical trials. In the 10-year time frame, 117 clinical trials started and 54 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 47 clinical trials started and 34 clinical trials were completed. i.e. 72.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "John Theurer Cancer Center at Hackensack University Medical Center" #1 sponsor was "Bristol-Myers Squibb" with 26 trials, followed by "Hackensack Meridian Health" with 16 trials sponsored, "Pfizer" with 14 trials sponsored, "Celgene" with 11 trials sponsored and "Georgetown University" with 11 trials sponsored. Other sponsors include 86 different institutions and companies that sponsored additional 70 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "John Theurer Cancer Center at Hackensack University Medical Center" #1 collaborator was "Bristol-Myers Squibb" with 6 trials as a collaborator, "Hackensack Meridian Health" with 6 trials as a collaborator, "Merck Sharp & Dohme LLC" with 6 trials as a collaborator, "AbbVie" with 3 trials as a collaborator and "Exelixis" with 3 trials as a collaborator. Other collaborators include 52 different institutions and companies that were collaborators in the rest 55 trials.

According to Clinical.Site data, the most researched conditions in "John Theurer Cancer Center at Hackensack University Medical Center" are "Multiple Myeloma" (24 trials), "Acute Myeloid Leukemia" (9 trials), "Melanoma" (8 trials), "Glioblastoma Multiforme" (6 trials) and "Advanced Solid Tumors" (5 trials). Many other conditions were trialed in "John Theurer Cancer Center at Hackensack University Medical Center" in a lesser frequency.

Most popular intervention types in "John Theurer Cancer Center at Hackensack University Medical Center" are "Drug" (150 trials), "Biological" (34 trials), "Other" (7 trials), "Genetic" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Nivolumab" (23 trials), "Dexamethasone" (16 trials), "Ipilimumab" (12 trials), "Cyclophosphamide" (10 trials) and "Placebo" (10 trials). Other intervention names were less common.

The vast majority of trials in "John Theurer Cancer Center at Hackensack University Medical Center" are 161 trials for "All" genders, 4 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "John Theurer Cancer Center at Hackensack University Medical Center". undefined are not yet recruiting, 49 are recruiting, 37 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 50 completed trials in John Theurer Cancer Center at Hackensack University Medical Center, 2 suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in John Theurer Cancer Center at Hackensack University Medical Center, 73 "Phase 1" clinical trials were conducted, 88 "Phase 2" clinical trials and 40 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".